ArticleFrontiers in pharmacology2026
Dual-targeting phytochemicals Ergosterol and Quercetagetin implicate steroid metabolism-associated pathways in lung and liver cancer models.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Targeted protein degradation dismantles undruggable targets to reverse immune evasion and therapy resistance in cancer.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Hormone-associated cancers use steroid metabolism to grow and avoid the immune system, while traditional treatments have to deal with drug resistance and systemic toxicity. Methods: This study is mainly divided into two parts. First, screening natural active ingredients for anti-lung cancer and anti-liver cancer and their network pharmacology research. Second, target identification and clinical drug design of potential medicinal components focusing on hormone metabolic pathways. Results and Discussion: We found that ergosterol and quercetagetin are dual-targeting phytochemicals that interfered with hormone metabolism in a potential contributing pathway through androgen receptor (AR) and estrogen receptor 1 (ESR1) and enzymes such as 3
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.